PMID- 28389258
OWN - NLM
STAT- MEDLINE
DCOM- 20180419
LR  - 20201209
IS  - 1522-9629 (Electronic)
IS  - 1094-5539 (Linking)
VI  - 45
DP  - 2017 Aug
TI  - Role of dual bronchodilators in COPD: A review of the current evidence for 
      indacaterol/glycopyrronium.
PG  - 19-33
LID - S1094-5539(17)30031-7 [pii]
LID - 10.1016/j.pupt.2017.04.002 [doi]
AB  - In this review, we summarize the rationale for combining long-acting 
      bronchodilators in the management of chronic obstructive pulmonary disease 
      (COPD), and the evidence for the long-acting bronchodilator combination 
      indacaterol/glycopyrronium (IND/GLY). Clinical practice guidelines generally 
      recommend the use of long-acting bronchodilators in the treatment of patients 
      with all severities of COPD, either as a first-choice or alternative-choice 
      therapy. Combining classes of long-acting bronchodilators can result in superior 
      improvements in lung function and clinical outcomes compared with bronchodilator 
      monotherapy, as observed in studies of free combinations of long-acting 
      beta(2)-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs). LABA/LAMA 
      fixed-dose combinations (FDCs) can also significantly improve lung function, 
      dyspnea, symptoms and health status and reduce exacerbations and rescue 
      medication use versus an inhaled corticosteroid/LABA, with a comparable safety 
      profile and lower incidence of pneumonia. The LABA/LAMA FDC of IND/GLY is 
      approved for use in the management of COPD. This review summarizes the evidence 
      for IND/GLY, including its pharmacodynamic and pharmacokinetic profile, and 
      published efficacy and safety data from clinical trials in patients with COPD. We 
      also explore the unmet needs in COPD and discuss the potential future of COPD 
      management.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Ficker, Joachim H
AU  - Ficker JH
AD  - Department for Respiratory Medicine, Allergology and Sleep Medicine, Nuernberg 
      General Hospital, Nuremberg, Germany; Department for Respiratory Medicine, 
      Allergology and Sleep Medicine, Paracelsus Medical University Nuernberg, 
      Nuremberg, Germany. Electronic address: ficker@klinikum-nuernberg.de.
FAU - Rabe, Klaus F
AU  - Rabe KF
AD  - Lung Clinic Grosshansdorf, and Department of Medicine Christian Albrecht 
      University Kiel, Kiel, Germany.
FAU - Welte, Tobias
AU  - Welte T
AD  - Department of Pulmonary and Infectious Diseases at Hannover University School of 
      Medicine, Hannover, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170404
PL  - England
TA  - Pulm Pharmacol Ther
JT  - Pulmonary pharmacology & therapeutics
JID - 9715279
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Glucocorticoids)
RN  - 0 (Indans)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Quinolones)
RN  - 0 (indacaterol-glycopyrronium combination)
RN  - V92SO9WP2I (Glycopyrrolate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenergic beta-2 Receptor Agonists/administration & dosage/adverse effects
MH  - Animals
MH  - Bronchodilator Agents/*administration & dosage/adverse effects/pharmacology
MH  - Drug Combinations
MH  - Glucocorticoids/administration & dosage/adverse effects
MH  - Glycopyrrolate/*administration & dosage/adverse effects/pharmacology
MH  - Humans
MH  - Indans/*administration & dosage/adverse effects/pharmacology
MH  - Muscarinic Antagonists/administration & dosage/adverse effects/pharmacology
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology
MH  - Quinolones/*administration & dosage/adverse effects/pharmacology
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - COPD
OT  - Dual bronchodilation
OT  - Glycopyrronium
OT  - Human
OT  - Indacaterol
OT  - QVA149
EDAT- 2017/04/09 06:00
MHDA- 2018/04/20 06:00
CRDT- 2017/04/09 06:00
PHST- 2017/01/27 00:00 [received]
PHST- 2017/03/29 00:00 [revised]
PHST- 2017/04/01 00:00 [accepted]
PHST- 2017/04/09 06:00 [pubmed]
PHST- 2018/04/20 06:00 [medline]
PHST- 2017/04/09 06:00 [entrez]
AID - S1094-5539(17)30031-7 [pii]
AID - 10.1016/j.pupt.2017.04.002 [doi]
PST - ppublish
SO  - Pulm Pharmacol Ther. 2017 Aug;45:19-33. doi: 10.1016/j.pupt.2017.04.002. Epub 
      2017 Apr 4.